非酒精性脂肪性肝病肝纤维化风险预测模型的应用与进展  

Application and progress of liver fibrosis risk prediction model for nonalcoholic fatty liver disease

作　　者：沈颖筱 施惠海[1] 罗家乐 张幸 徐婷 郭鹤鸣 周春晓 SHEN Yingxiao;SHI Huihai;LUO Jiale;ZHANG Xing;XU Ting;GUO Heming;ZHOU Chunxiao(Department of Gastroenterology,the Affiliated Suzhou Hospital of Nanjing Medical University,Headquarters of Suzhou Municipal Hospital,Suzhou,Jiangsu,215000;Department of Endocrinology,the Second Hospital Affiliated to Soochow University,Suzhou,Jiangsu,215000)

机构地区：[1]南京医科大学附属苏州医院/江苏省苏州市立医院本部消化科,江苏苏州215000 [2]苏州大学附属第二医院内分泌科,江苏苏州215000

出　　处：《实用临床医药杂志》2023年第9期131-136,142,共7页Journal of Clinical Medicine in Practice

基　　金：国家自然科学基金项目(82100881)。

摘　　要：非酒精性脂肪性肝病发病率逐年上升,脂肪肝肝纤维化的早期评估和早期干预对于改善非酒精性脂肪性肝病患者的预后至关重要。非侵入性的风险预测模型在临床实践中越来越受到重视。本文基于临床指标及不同算法,系统回顾了各类肝纤维化预测模型的优势及局限性,分析阐述了各模型的特点及在临床中的使用价值。The incidence of non-alcoholic fatty liver disease is increasing year by year.Early evaluation and early intervention of fatty liver fibrosis are very important for improving the prognosis of patients with non-alcoholic fatty liver disease.Non-invasive prediction models have been paid more and more attention in clinical practice.Based on different clinical indexes and algorithms,the article systematically reviewed the advantages and limitations ofvarious models for predicting liver fibrosis,and analyzed the characteristics of each model and its value.

关 键 词：非酒精性脂肪性肝病 预测模型 肝纤维化 肝硬化 生物标志物 早期干预 

分 类 号：R589.2[医药卫生—内分泌] R575.1[医药卫生—内科学]